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The Platform Trial
An Efficient Strategy for Evaluating
Multiple Treatments
The drug development enterprise is struggling. The development of new therapies is limited by high costs, slow
progress, and a high failure rate, even in the late stages
of development. Clinical trials are most commonly based
on a “one population, one drug, one disease” strategy,
in which the clinical trial infrastructure is created to test
a single treatment in a homogeneous population.
This approach has been largely unsuccessful for multiple diseases, including sepsis, dementia, and stroke. Despite promising preclinical and early human trials, there
have been numerous negative phase 3 trials of treatments for Alzheimer disease1 and more than 40 negative phase 3 trials of neuroprotectants for stroke.2 Effective treatments for such diseases will likely require
combining treatments to affect multiple targets in complex cellular pathways and, perhaps, tailoring treatments to subgroups defined by genetic, proteomic,
metabolomic, or other markers.3
There has been increasing interest in efficient trial
strategies designed to evaluate multiple treatments and
combinations of treatments, in heterogeneous patient
populations, with the capability to add new treatments
in the future and eliminate investigational treatments
lacking efficacy. The term “platform trial” is sometimes
used to describe trials designed with these goals in mind,
signifying the intent to build an experimental platform
that will exist after the evaluation of any particular
treatment.4 Currently, platform trials are enrolling patients or are under development in oncology, infectious diseases, neurology, and intensive care.
Platform trials are an extension of adaptive trial design. An adaptive trial allows prespecified changes in key
trial characteristics during the conduct of the trial in response to information accumulating during the trial;
however, most adaptive trials focus on evaluating a single
treatment in a single population. Examples of adaptive
trials include traditional group-sequential trials, as well
as trials incorporating reestimation of sample size or
using variable randomization proportions (responseadaptive randomization).5 A platform trial is a type of
adaptive trial designed to evaluate multiple treatments
efficiently.

The Problem: Evaluating Multiple Treatments
Efficiently
Although conventional 2-group clinical trials are simple,
using such trials is inefficient when evaluating a series
of therapies sequentially, both because a separate control population is required for each comparison and because data on different treatments may not be truly comparable. Use of such trials also may fail to detect real

benefits when evaluating potentially synergistic combination treatments (eg, treatment A, treatment B, treatment C, and all combinations) if the starting point is the
testing of each treatment in isolation.

What Is a Platform Trial?
A platform trial is defined by the broad goal of finding the
best treatment for a disease by simultaneously investigating multiple treatments, using specialized statistical tools
forallocatingpatientsandanalyzingresults.Thefocusison
thediseaseratherthananyparticularexperimentaltherapy.
A platform trial is often intended to continue beyond the
evaluationoftheinitialtreatmentsandtoinvestigatetreatment combinations, to quantify differences in treatment
effects in subgroups, and to treat patients as effectively as
possible within the trial. Although some of the statistical
toolsusedinplatformtrialsarefrequentlyusedinothersettingsandsomelessso,itistheintegratedapplicationofmultipletoolsthatallowsaplatformtrialtoaddressitsmultiple
goals. The Table summarizes the general differences between a traditional clinical trial and a platform trial.
During a platform trial, accumulating outcome data
can be used to adjust the randomization probabilities to
preferentially assign better-performing treatment regimens to future patients. This approach, responseadaptive randomization, improves the outcomes of
study participants treated within the trial, increases the
available information on treatment effects and adverse
effects for the most effective treatments, and shortens
the evaluation time for the best therapies.5
The heterogeneity of the patient population (eg,
based on biomarkers, tumor genetics, illness severity, disease risk factors, or age) is considered explicitly in many
platform trials, with the goal of finding the best treatment for patient subgroups defined by these characteristics. These confounding factors often have substantial effects on outcome—effects that may be larger than
the likely benefit of the treatments being investigated.
In a platform trial, all patients in the trial, even patients
assigned treatments no longer under investigation, help
in understanding and adjusting for the effects of confounding and secular trends.
Platform trials use decision rules (eg, based on the
likelihood of a treatment benefit or of success in a future confirmatory trial6) to determine when a given treatment regimen has demonstrated sufficient efficacy to
“graduate” from the trial and proceed to the next stage
in development or to be used clinically. Bayesian probabilities can also be used to determine when a treatment should be eliminated from the trial, or from subgroups of patients, because it is no longer sufficiently
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Table. General Characteristics of Traditional and Platform Trialsa

a

Characteristic

Traditional Trial

Platform Trial

Scope

Efficacy of a single agent in a homogeneous population

Evaluating efficacy of multiple agents in a heterogeneous population;
explicitly assumes treatment effects may be heterogeneous

Duration

Finite, based on time required to answer the single
primary question

Potentially long-term, as long as there are suitable treatments
requiring evaluation

No. of treatment groups

Prespecified and generally limited

Multiple treatment groups; the number of treatment groups and the
specific treatments may change over time

Stopping rules

The entire trial may be stopped early for success or
futility or harm, based on the apparent efficacy of the
single experimental treatment

Individual treatment groups may be removed from the trial, based on
demonstrated efficacy or futility or harm, but the trial continues,
perhaps with the addition of new experimental treatment(s)

Allocation strategy

Fixed randomization

Response-adaptive randomization

Sponsor support

Supported by a single federal or industrial sponsor

The trial infrastructure may be supported by multiple federal
or industrial sponsors or a combination

Platform trials and similar trials may also be called basket, bucket, umbrella, or standing trials.

promising. Once a treatment is discontinued, it may be replaced by
a new treatment. An example demonstrating how a platform trial
may progress over time is shown in the eFigure in the Supplement.
Because a platform trial constitutes a long-term resource that
can be used to evaluate multiple treatments, sources of financial support may combine federal, foundation, and for-profit entities. Substantial resources can be saved by the use of the same trial infrastructure to evaluate multiple therapies. This approach also allows
participants access to treatments from different companies, with
treatment allocation guided by experience within the trial, rather than
having their options limited by the choice of trial.

Example Platform Trials
The I-SPY 2 clinical trial is a phase 2 platform trial of neoadjuvant
therapy in women with breast cancer.7 Subgroups of women are defined by 3 genetic markers to define 8 separate genetic subgroups,
organized into 10 “signatures” that represent clinically meaningful
groupings. Patients are adaptively randomized within their genetic
subgroup. Treatments showing efficacy in 1 or more signature groups
of women, based on the probability of success in the confirmatory
phase 3 trial, are “graduated” from the trial for evaluation in separate confirmatory trials.
In late 2013, the Innovative Medicines Initiative of the European
Union announced a call for proposals, supported by more than
€50 million, to build a Bayesian platform trial for the prevention of
Alzheimer disease.8 The long-term trial will evaluate multiple
treatments, from multiple sponsors, for persons at high risk for

Conclusions
Currently, researchers generally design trials to investigate 1 drug at
a time, in homogeneous patient populations. Platform trials have the
potential to accelerate efforts to identify effective treatments, especially combination treatments and treatments tailored to particular subgroups of patients, for challenging diseases. Realizing the
potential of this approach will require continued teamwork and innovation in statistical methodology, clinical trial logistics and coordination, and a willingness to prioritize the goal of finding effective
treatment over the evaluation of any single individual therapy.
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